Open observational study of galantamine hydrobromide (Reminyl) administration for the treatment of patients with mild to moderate dementia of the Alzheimer type.
Phase of Trial: Phase IV
Latest Information Update: 23 Mar 2012
At a glance
- Drugs Galantamine (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Sponsors Janssen-Cilag
- 06 Oct 2009 Actual patient number (344) added as reported by ClinicalTrials.gov.
- 19 Oct 2007 Status changed from in progress to completed.
- 14 Oct 2006 New trial record.